Document Detail

Extracorporeal photochemotherapy for treatment of drug-resistant graft-vs.-host disease.
MedLine Citation:
PMID:  9701389     Owner:  NLM     Status:  MEDLINE    
Extracorporeal photochemotherapy (EP) is a therapeutic approach to the treatment of drug-resistant graft-vs.-host disease (GVHD) that uses the known immunosuppressive and immunomodulatory effects of ultraviolet light. In 1990, we initiated a pilot study to evaluate the efficacy and safety of EP in patients with refractory GVHD. Between 1991 and 1996, six patients with acute grade IV liver GVHD, 12 patients with chronic following acute GVHD, and six patients with de novo chronic GVHD were treated with EP. All patients had failed to respond to conventional GVHD immunosuppressive drug therapy of cyclosporine and prednisone. The six patients with acute liver GVHD had also received antithymocyte globulin (ATG); therapy for chronic GVHD included thalidomide in eight patients, psoralen plus ultraviolet A in five patients, and ATG in two patients. All patients with acute liver GVHD had progressive liver failure with short survival despite frequent EP. The response rate with EP treatment was 3 of 6 for patients with de novo chronic GVHD and 3 of 12 for patients with chronic following acute GVHD. Three patients with bronchiolitis obliterans had either no response or no documented disease progression while undergoing EP. Side effects of EP were minor and included gastrointestinal upset frequently, catheter-related sepsis in four patients, increased red blood cell and platelet transfusion requirements in one patient, and leukopenia in two patients. EP was discontinued in three patients because of side effects, including GI upset in one patient and bone marrow suppression in two patients. Side effects were reversible with the discontinuation of EP. We were unable to correlate response to EP with the level of methoxypsoralen, number of lymphocytes treated, or pattern of pre- and posttreatment CD4/CD8 ratio. We concluded that EP has some efficacy in the treatment of drug-resistant chronic GVHD, with minor overall toxicity.
E P Smith; I Sniecinski; A C Dagis; P M Parker; D S Snyder; A S Stein; A Nademanee; M R O'Donnell; A Molina; G M Schmidt; D E Stepan; N Kapoor; J C Niland; S J Forman
Related Documents :
15248099 - Clinical presentations of patients with polyol abnormalities.
950079 - Marked increase in serum levels of liver enzymes in patients receiving chenic acid and ...
20815829 - Duloxetine hepatotoxicity: a case-series from the drug-induced liver injury network.
15660889 - Alagille syndrome: cutaneous manifestations in 38 children.
16293559 - Abnormal glucose tolerance is a predictor of steatohepatitis and fibrosis in patients w...
2468869 - Disposition of nitrendipine in patients with chronic liver diseases.
7540759 - Trypsinogen and other pancreatic enzymes in patients with renal disease: a comparison o...
8283069 - Improving nlep performance in a low endemic area.
17166519 - Progressive myoclonic epilepsy: a clinical, electrophysiological and pathological study...
Publication Detail:
Type:  Clinical Trial; Journal Article; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation     Volume:  4     ISSN:  1083-8791     ISO Abbreviation:  Biol. Blood Marrow Transplant.     Publication Date:  1998  
Date Detail:
Created Date:  1998-11-10     Completed Date:  1998-11-10     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  9600628     Medline TA:  Biol Blood Marrow Transplant     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  27-37     Citation Subset:  IM    
University of Wisconsin Medical School, Madison 53792, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Bone Marrow Transplantation / adverse effects*
Drug Resistance
Ficusin / therapeutic use
Graft vs Host Disease / etiology,  therapy*
Immunosuppressive Agents / pharmacology,  therapeutic use
Middle Aged
PUVA Therapy*
Photosensitizing Agents / therapeutic use
Transplantation, Homologous
Treatment Outcome
Grant Support
Reg. No./Substance:
0/Immunosuppressive Agents; 0/Photosensitizing Agents; 66-97-7/Ficusin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Intravenous immunoglobulin and the risk of hepatic veno-occlusive disease after bone marrow transpla...
Next Document:  Efficacy of autologous peripheral blood stem cell (PBSC) harvest and engraftment after ablative chem...